FDA Approves Monthly Lecanemab for Early-Stage Alzheimer Disease: Daily Dose
Your daily dose of the clinical news you may have missed.
Symbravo Mechanism of Action and Patient Selection, with PI Stewart Tepper, MD
Tepper, principal investigator for phase 3 trials of Symbravo as acute treatment for migraine in adults, reviews the new drug's dual MOA and target patient populations.
Optimizing PTSD Treatment: The Role of Brexpiprazole and Sertraline in Future Guidelines
Brexpiprazole and sertraline showed promise for PTSD treatment in a recent study. Lead author, Lori Davis, MD, discusses clinical findings, treatment guidelines, and future research directions.
COVID-19 Associated with Higher Long-Term Mortality Than Flu or RSV: New Data
Researchers found that COVID-19 had a higher long-term mortality than influenza and RSV in veterans—underscoring vaccination’s vital role.
Where Will the New Nonopioiod Suzetrigine (Journavx) Fit Best Along the Acute Pain Management Continuum? Phase 3 Investigator Shares Thoughts
Suzetrigine (Journavx) PI Todd Bertoch, MD, identifies the sweet spot where he thinks the new NaV1.8 inhibitor will be most effective in post-surgical and other moderate-to-severe acute pain.
Global Migraine Burden Rising Fastest Among Men and Adolescents, New Research Finds
The global burden of migraine rose by 58% between 1990 and 2021 to more than 1 billion, a pace projected to continue and most rapidly among men and young people.
Stool Tests Still Top Choice for CRC Screening: Daily Dose
7 Drugs Approved for Primary Care: Q4 2024
An oral antibiotic for drug-resistant UTIs, a long-awaited therapy for congenital adrenal hyperplasia, and more.
Propranolol May Lower Stroke Risk in Women with Migraine, Study Finds
Data set to be presented at ISC 2025 shows that the protective effect of propranolol was stronger for ischemic stroke compared to other stroke types.
Symbravo (AXS-07) for Treatment of Acute Migraine in Adults: Phase 3 Trial Primer
The pivotal INTERCEPT and MOMENTUM phase 3 clinical trials served as foundational evidence for the efficacy of the combination therapy across migraine presentations.
Pain Expert Edward Mariano, MD, MAS, Highlights Journavx and the Newly-Approved Nonopioid's Mechanism of Action
Mariano, a well-known researcher in regional anesthesiology and acute pain medicine, talks about the Journavx difference, including the drug's safety profile.
FDA Approves First Monotherapy Standalone MDD Treatment: Daily Dose
Journavx Approval: Lead Investigator Highlights Pivotal Phase 3 Clinical Trials
Todd Bertoch, MD, reviews the significant findings on relief of pain from the 2 pivotal studies and lauds the remarkable safety profile of the novel nonopoid analgesic Journavx.
FDA Approves Journavx, First-in-Class Nonopioid Analgesic for Moderate-to-Severe Acute Pain
Journavx is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years.
Axsome Therapeutics: FDA Approves Symbravo for Acute Treatment of Migraine
A single oral dose of Symbravo provided rapid migraine pain freedom and return to normal functioning within 2 hours, and sustained efficacy through 24 and 48 hours.
5 Drug Classes Linked to Increased Fall Risk Among Adults with COPD Near End of Life
Investigational RSV Antiviral Treatment Reduces Viral Load in Phase 2 Human Challenge Trial
The study of S-337395 showed an 88.9% reduction in RSV viral load and symptom improvement in the highest dose group, with no severe adverse events reported.
Furosemide Fails to Reduce Risk of Dangerous de novo Postpartum Hypertension: New Research
Close monitoring for dnPPHTN during the first 2 weeks post-delivery is highly recommended for women determined to be at high risk for the hypertensive disorder of pregnancy.
Tool Predicts Age at Cognitive Impairment, Dementia Onset: Daily Dose
PTSD Treatment Advancements: Brexpiprazole-Sertraline Offers New Hope in Phase 3 Trial
Data showed that brexpiprazole plus sertraline significantly improved PTSD symptoms vs sertraline alone. Lead author, Lori Davis, MD, discusses more.
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Fall Risk Near End of Life in COPD / image credit ©Toa555/shutterstock.com")
